Galectin Therapeutics Inc. (GALT)

[thefamilyman]

Here is the blurb from BTA. The key phrase is "I'm doubting results of upcoming trials." With the dilution and this type of publicity, we may be in for a long slow slide to less than a buck a share...

"This is another inherited stock from the previous editor that unfortunately failed in an important Phase 1 study in 2014 and has never recovered, despite the fact that it has two promising drugs for melanoma in Phase 1 trials, two promising liver disease drugs in Phase 2 trials and a psoriasis drug in Phase 2 trials. I knew we’d have to wait about two years until a Phase 2 trial reported out to see a comeback in this company. Now I’m not so sure what to be hopeful for, and I’m doubting results of upcoming trials. Galectin fell below our buy-in price of $3.60 during recent biotech kerfuffle, but it is coming back. When it gets to approximately $3.60, or whatever price you bought it for originally, I’d suggest you sell. No losses should be necessary, but don’t get greedy for much of a gain. Get out at breakeven and be grateful. I’ll keep you updated when the time is right."